Immuno-oncology Drugs Market Size, Trends and Forecast to 2030

Q: Which is the leading disease type segment in the market?

Melanoma is the leading disease type segment in the market Read more

Immuno-oncology drugs target the body’s natural defenses, the immune system, to fight cancer. Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Immuno-oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies. There are also different types of drugs available to help treat the side effects from oncology drugs. Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

The global Immuno-oncology drugs market is estimated to be valued at US$ 17,394.2 million in 2022 and is expected to exhibit a CAGR of 16.8% during the forecast period (2022-2030).

Figure 1. Global Immuno-oncology Drugs Market Share (%), by Disease Type, 2022

Global Immuno-oncology Drugs Market - Drivers

Increasing adoption of organic strategies such as funding by key market players is expected to drive the global Immuno-oncology drugs market growth over the forecast period. For instance, in July 2020, Agenus Inc., a biotechnology company, announced the closing of a US$ 20 million equity investment, at US$ 4.03 per share, by Betta Pharmaceuticals Co., Ltd., bringing the total received to US$ 35M. This funding will enable Betta to receive exclusive rights for the development and commercialization of balstilimab and zalifrelimab, as both monotherapies and combination therapies, excluding intravesical delivery, in greater China.

Immuno-oncology Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 17,394.2 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	16.8%	2030 Value Projection:	US$ 60,186.2 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Treatment Type: Immune Checkpoint Inhibitors ( PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others By Disease Type: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others (Breast Cancer, Thyroid Cancer, etc.) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
Growth Drivers:	Factors such as increasing adoption of inorganic strategies such as product approval and funding by key market players
Restraints & Challenges:	Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration

Figure 2. Global Immuno-oncology Drugs Market Value (US$ Million), by Region, 2022

Global Immuno-oncology Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global Immuno-oncology drugs market. For instance, in October 2020, according to the data published in Nature Cancer journal, cancer patients are at higher risk of COVID-19 infections which is described by the immune responses that confer adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer. As COVID -19 is severe respiratory infection and linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Hence, the management of oncology patients is the major challenge during COVID-19.

Global Immuno-oncology Drugs Market: Key Developments

Increasing adoption of inorganic strategies such as product approval by key market players is expected to drive global Immuno-oncology drugs market. For instance, in July 2022, CStone Pharmaceuticals, a bio-pharmaceutical company, announced the new drug application for GAVRETO (pralsetinib) has been approved in Hong Kong, China for the treatment of adult patients with rearranged during transfection fusion-positive metastatic non-small cell lung cancer.

Global Immuno-oncology Drugs Market: Restraint

Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration is expected to hinder the market growth. For instance, in May 2022, the U.S. Food and Drug Administration recalled 2 lots of Mvasi (bevacizumab-awwb) injection due to defective containers, which was manufactured by Amgen Inc., a Biotechnology company. MVASI is indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer.

Global Immuno-oncology Drugs Market - Key Players

Major players operating in the global immuno-oncology drugs market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE

Frequently Asked Questions

The global immuno-oncology drugs market size is estimated to be valued at US$ 17,394.2 million in 2022 and is expected to exhibit a CAGR of 16.8% between 2022 and 2030.

Factors such as increasing adoption of inorganic strategies such as product approval and funding by key market players are expected to drive the market

Melanoma is the leading disease type segment in the market

Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration are the major factors hampering growth of the market

Major players operating in the market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE